AUPH News and Press, Aurinia Pharmaceuticals Inc From 02/15/24

2024-02-15 15:00:53 ET Summary Aurinia Pharmaceuticals Inc. stock price dropped 25% after underwhelming Q4 and full-year 2023 results. Sales of Lupkynis, indicated for lupus nephritis and the company's only commercial product, have failed to meet expectations. Aurinia has init...

2024-02-15 10:10:28 ET Aurinia Pharmaceuticals Inc. (AUPH) Q4 2023 Earnings Conference Call February 15, 2024 08:30 AM ET Company Participants Andrea Christopher - Head, Corporate Communications & Investor Relations Peter Greenleaf - Chief Executive Officer J...

2024-02-15 07:05:36 ET More on Aurinia Pharma Aurinia Pharmaceuticals: Sales Growth Would Help Buyout Potential Aurinia Pharmaceuticals: A Post Q3 Earnings Assessment Aurinia Pharma GAAP EPS of -$0.19 misses by $0.03, revenue of $45.1M misses by $0.06M Aurini...

2024-02-15 06:02:11 ET Aurinia Pharma press release ( NASDAQ: AUPH ): Q4 GAAP EPS of -$0.19 misses by $0.03 . Revenue of $45.1M (+58.8% Y/Y) misses by $0.06M . Shares -3.6% PM. $350.7 million of cash, cash equivalents, restricted cash and investment...

Propanc Biopharma Inc (PPCB) is expected to report for Q2 2024 Bank of Georgia Group Plc (BDGSF) is expected to report for quarter end 2023-12-31 Arch Resources Inc. Class A (ARCH) is expected to report $6.9 for Q4 2023 Bloom Energy Corporation Class A (BE) is expected to report $-0.0...

Total net revenue was $45.1 million and $175.5 million, and net product revenue was $42.3 million and $158.5 million, for the fourth quarter and full year 2023, respectively $350.7 million of cash, cash equivalents, restricted cash and investments as of December 31, 2023 Reaffirms 2024 ne...

2024-02-14 10:53:15 ET More on Aurinia Pharma Aurinia Pharmaceuticals: Sales Growth Would Help Buyout Potential Aurinia Pharmaceuticals: A Post Q3 Earnings Assessment Aurinia Pharmaceuticals sees strong Q4 revenue growth, eyes cash flow positivity Aurinia Pha...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release 2023 fourth quarter and full year financial and operational results on Thursday, February 15, 2024, before markets open. Aurinia’s management team will host a conference call/webcast a...

2024-01-27 20:45:52 ET Summary Speculation about an AUPH buyout continues as the company continues to review strategic options. AUPH has had a few quarters of fairly flat net product revenues. AUPH is nonetheless guiding for net product revenues of $200M-$220M in 2024, compare...

2024-01-19 16:55:57 ET Gainers: Vanda Pharmaceuticals  ( VNDA ) +5% . Edgewise Therapeutics ( EWTX ) +3% . Rush Enterprises ( RUSHA ) +2% . Cricut ( CRCT ) +2% . EchoStar Corporation ( SATS ) +2% . Losers: Fusion Pha...